ArticleScientific reports2025
Association of serum trace elements with non-invasive fibrosis scores in metabolic dysfunction-associated steatotic liver disease.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Liver biopsy is not a routine screening tool for detecting fibrosis progression in metabolic dysfunction-associated steatotic liver disease (MASLD). Noninvasive methods based on serum biomarkers are used instead. This study evaluated the relationship between serum zinc (Zn), copper (Cu), and ceruloplasmin levels and non-invasive criteria for hepatic fibrosis, including Fibrosis-4 (FIB-4), Nonalcoholic Fatty Liver Disease fibrosis score (NFS), and BARD, in patients with MASLD. In this prospective cross-sectional study, a total of 134 MASLD patients referred to the gastroenterology clinic of Imam Reza Hospital and Sheikh AlRaees Clinic, Tabriz, in 2022 were included. Serum levels of Zn, Cu, ceruloplasmin, albumin, complete blood count (CBC), fasting blood sugar (FBS), Alanine aminotransferase (ALT), and aspartate aminotransferase (AST) were checked. Also, non-invasive measures of FIB-4, NFS, and BARD were measured. Finally, the relationship between the levels of Zn, Cu, and ceruloplasmin with each of the FIB-4, NFS, and BARD criteria was investigated. Zn serum levels were significantly lower in FIB-4 3 than in FIB-4 1 and 2 (P-value < 0.01); however, no significant relationship was found between serum Cu and ceruloplasmin variables with FIB-4 (P > 0.05). Zn serum levels were also significantly higher in NFS fibrosis score 1 (P-value < 0.01). There was no significant relationship between serum Cu and ceruloplasmin variables with NFS fibrosis score in the studied patients (P > 0.05). No significant relationship was observed between serum Zn, Cu, and ceruloplasmin with the BARD fibrosis score in the studied patients (P > 0.05). It seems that among the levels of Zn, Cu, and ceruloplasmin serum with non-invasive measures of liver fibrosis, including FIB-4, NFS, and BARD in MASLD patients, there is only a significant relationship between serum Zn level and FIB-4 and NFS criteria. And therefore, Zn may serve as a potential biomarker.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.